Bicara Therapeutics (BCAX) Free Cash Flow (2023 - 2026)
Bicara Therapeutics posted quarterly Free Cash Flow of -$37.6 million for Q1 2026, down 33.67% year-on-year from -$56.6 million in Q1 2025, and down 55.73% on a QoQ basis from -$24.1 million in Q4 2025.
Bicara Therapeutics (BCAX) has 4 years of Free Cash Flow data on file, last reported at -$37.6 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 33.67% year-over-year to -$37.6 million; the trailing twelve-month figure through Mar 2026 stood at -$116.6 million (down 31.97% YoY), and the FY2025 full-year result was -$107.1 million, down 43.16% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$37.6 million, down from -$24.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.5 million in Q4 2023 and bottomed at -$37.6 million in Q1 2026.
- The 4-year median for Free Cash Flow is -$24.9 million (2025), against an average of -$22.8 million.
- The widest annual swing landed in 2024, when Free Cash Flow sank 254.96%; it then climbed 19.78% in 2025.
- A 4-year view of Free Cash Flow shows it stood at -$8.5 million in 2023, then tumbled by 254.96% to -$30.1 million in 2024, then gained by 19.78% to -$24.1 million in 2025, then slumped by 55.73% to -$37.6 million in 2026.
- The last three Free Cash Flow figures came in at -$37.6 million (Q1 2026), -$24.1 million (Q4 2025), and -$29.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Bicara Therapeutics | 1.25 Bn | 1.25 Bn | - | -37.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.57 Mn |
| Mar 31, 2026 | -37.57 Mn |
| Dec 31, 2025 | -24.12 Mn |
| Dec 31, 2025 | -24.12 Mn |
| Sep 30, 2025 | -29.29 Mn |
| Sep 30, 2025 | -29.29 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Mar 31, 2025 | -28.11 Mn |
| Mar 31, 2025 | -28.11 Mn |
| Dec 31, 2024 | -30.07 Mn |
| Dec 31, 2024 | -30.07 Mn |
| Sep 30, 2024 | -17.23 Mn |
| Sep 30, 2024 | -17.23 Mn |
| Jun 30, 2024 | -12.93 Mn |
| Jun 30, 2024 | -12.93 Mn |
| Mar 31, 2024 | -14.59 Mn |
| Mar 31, 2024 | -14.59 Mn |
| Dec 31, 2023 | -8.47 Mn |
| Dec 31, 2023 | -8.47 Mn |